IGI

Collaboration
propels innovation

Who we are

IGI, Inc. is a global, clinical-stage biotechnology company focused on developing innovative biologics in oncology. Headquartered in New York, NY, IGI is advancing a robust pipeline of novel, first-in-class Multispecifics^TM aimed at addressing complex diseases and treating patients holistically. Powered by its proprietary BEAT^® technology platform, IGI is committed to delivering breakthrough curative therapies to improve and extend the lives of patients battling hematological malignancies and solid tumors.

At a Glance

Innovation at IGI
Leadership
Centers of Innovation

Innovation at IGI

Diversity of immune cell engagement and indications across hematologic and solid tumors
Proprietary protein engineering platform allowing maximal flexibility and manufacturability of full length multispecific antibodies
Discovery engine to sustain innovation and drive long-term growth

Leadership

A highly experienced management team with combined experience of 120+ years
Approximately 100 employees are singularly focused on pushing the boundaries of oncology cancer treatment/therapy
Scientific Advisory Board with extensive expertise in innovative drug development, immuno-oncology, and protein engineering

Centers of Innovation

3 state-of-the-art centers of innovation in USA, Switzerland and India

Company headquarters in New York, USA, focused on clinical development, general and administration
Process Development, Manufacturing, Finance, and Legal teams are located in La Chaux-de-Fonds, Neuchâtel and the Research Center at Biopole, Lausanne in Switzerland
R&D support hub at Mahape in Mumbai, India